Analyst: Diagnostics Sector R&D Spending Won't Match FDA Data Demands
This article was originally published in The Gray Sheet
Executive Summary
The R&D spend to revenue ratio at emerging and established pure-play diagnostic companies is not sufficient to meet growing FDA requirements for the space, a Morgan Stanley analyst argues.
You may also be interested in...
Abbott Follows Pfizer To FDA With Co-Developed Lung Cancer Diagnostic
A 2009 collaboration agreement with Pfizer could start bearing fruit for Abbott Molecular by year end, with the firms' lung cancer drug-diagnostic combination now under review at FDA.
FDA: Draft Guidance For Laboratory-Developed Test Regs Taking Extra Time
The head of FDA’s diagnostics office is hopeful that draft guidance governing laboratory-developed tests will be issued by year-end, but cautioned that the process is taking more time than expected.
EU Experts Want One-Stop-Shop EU Governance That Mimics Best Of Other Jurisdictions
It may be blue sky thinking to surmise how a new EU medtech regulatory governance structure could evolve. But with change on the horizon, experts see exciting opportunities.